Testosterone Replacement Therapy and Prostate Cancer Incidence

Overview

Journal World J Mens Health

Date 2016 Jan 16

PMID 26770932

Citations 9

Authors

Michael Louis Eisenberg

Affiliations

Soon will be listed here.

Abstract

While early studies demonstrated a positive association between testosterone and prostate cancer, evidence on the nature of the relationship has evolved with time and newer data. Studies examining links between baseline testosterone levels as well as testosterone therapy and incident prostate cancer, reveal a more complex relationship. Moreover, investigators have reported their initial experiences with supplementing testosterone in men with a history of both treated and untreated prostate cancer.

Citing Articles

Effect of Elderberry ( L.) Extract Intake on Normalizing Testosterone Concentration in Testosterone Deficiency Syndrome Rat Model Through Regulation of 17β-HSD, 5α-Reductase, and CYP19A1 Expression.

Kim J, An J, Song Y, Jang M, Kong H, Kim S Nutrients. 2024; 16(23).

PMID: 39683564 PMC: 11644235. DOI: 10.3390/nu16234169.

Voiding function improves under long-term testosterone treatment (TTh) in hypogonadal men, independent of prostate size.

Yassin A, Alwani M, Al-Zoubi R, Aboumarzouk O, Talib R, Nettleship J Int Urol Nephrol. 2023; 55(7):1649-1658.

PMID: 37148486 PMC: 10293434. DOI: 10.1007/s11255-023-03602-4.

An Individualized Approach to Managing Testosterone Therapy in the Primary Care Setting.

Dobs A, Campbell K Int J Gen Med. 2022; 15:7719-7733.

PMID: 36238539 PMC: 9552794. DOI: 10.2147/IJGM.S364189.

Burden of Male Hypogonadism and Major Comorbidities, and the Clinical, Economic, and Humanistic Benefits of Testosterone Therapy: A Narrative Review.

Yeo S, Holl K, Penaherrera N, Wissinger U, Anstee K, Wyn R Clinicoecon Outcomes Res. 2021; 13:31-38.

PMID: 33488103 PMC: 7814241. DOI: 10.2147/CEOR.S285434.

Impact and Outcomes of Pretreatment Total Serum Testosterone on Localized Prostate Cancer Patients.

Usera B, Creveling P, Tward J Prostate Cancer. 2020; 2020:8357452.

PMID: 32395350 PMC: 7201500. DOI: 10.1155/2020/8357452.

References

Shin B, Hwang E, Im C, Kim S, Jung S, Kang T . Is a decreased serum testosterone level a risk factor for prostate cancer? A cohort study of korean men. Korean J Urol. 2011; 51(12):819-23. PMC: 3016426. DOI: 10.4111/kju.2010.51.12.819. View

Morgentaler A, Rhoden E . Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology. 2006; 68(6):1263-7. DOI: 10.1016/j.urology.2006.08.1058. View

Dean J, Carnegie C, Rodzvilla J, Smith T . Long-term effects of testim(r) 1% testosterone gel in hypogonadal men. Rev Urol. 2006; 6 Suppl 6:S22-9. PMC: 1472880. View

Pastuszak A, Pearlman A, Godoy G, Miles B, Lipshultz L, Khera M . Testosterone replacement therapy in the setting of prostate cancer treated with radiation. Int J Impot Res. 2012; 25(1):24-8. DOI: 10.1038/ijir.2012.29. View

Sarosdy M . Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2006; 109(3):536-41. DOI: 10.1002/cncr.22438. View

Muller R, Gerber L, Moreira D, Andriole G, Castro-Santamaria R, Freedland S . Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. Eur Urol. 2012; 62(5):757-64. DOI: 10.1016/j.eururo.2012.05.025. View

Calof O, Singh A, Lee M, Kenny A, Urban R, Tenover J . Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005; 60(11):1451-7. DOI: 10.1093/gerona/60.11.1451. View

Kenny A, Kleppinger A, Annis K, Rathier M, Browner B, Judge J . Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc. 2010; 58(6):1134-43. PMC: 3014265. DOI: 10.1111/j.1532-5415.2010.02865.x. View

Bhasin S, Cunningham G, Hayes F, Matsumoto A, Snyder P, Swerdloff R . Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010; 95(6):2536-59. DOI: 10.1210/jc.2009-2354. View

10.

Leibowitz R, Dorff T, Tucker S, Symanowski J, Vogelzang N . Testosterone replacement in prostate cancer survivors with hypogonadal symptoms. BJU Int. 2009; 105(10):1397-401. DOI: 10.1111/j.1464-410X.2009.08980.x. View

11.

Pastuszak A, Pearlman A, Lai W, Godoy G, Sathyamoorthy K, Liu J . Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013; 190(2):639-44. PMC: 4544840. DOI: 10.1016/j.juro.2013.02.002. View

12.

Kim H, Hoon Kim B, Park C, Il Kim C . Usefulness of preoperative serum testosterone as a predictor of extraprostatic extension and biochemical recurrence. Korean J Urol. 2012; 53(1):9-13. PMC: 3272561. DOI: 10.4111/kju.2012.53.1.9. View

13.

Lane B, Stephenson A, Magi-Galluzzi C, Lakin M, Klein E . Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. Urology. 2008; 72(6):1240-5. DOI: 10.1016/j.urology.2008.06.001. View

14.

Bhattacharya R, Khera M, Blick G, Kushner H, Nguyen D, Miner M . Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS). BMC Endocr Disord. 2011; 11:18. PMC: 3217857. DOI: 10.1186/1472-6823-11-18. View

15.

Bhasin S, Storer T, Berman N, Yarasheski K, Clevenger B, Phillips J . Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab. 1997; 82(2):407-13. DOI: 10.1210/jcem.82.2.3733. View

16.

Porcaro A, Petrozziello A, Ghimenton C, Migliorini F, Sava T, Caruso B . Associations of pretreatment serum total testosterone measurements with pathology-detected Gleason score cancer. Urol Int. 2013; 93(3):269-78. DOI: 10.1159/000354621. View

17.

Pastuszak A, Khanna A, Badhiwala N, Morgentaler A, Hult M, Conners W . Testosterone Therapy after Radiation Therapy for Low, Intermediate and High Risk Prostate Cancer. J Urol. 2015; 194(5):1271-6. DOI: 10.1016/j.juro.2015.05.084. View

18.

Morgentaler A . Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol. 2006; 50(5):935-9. DOI: 10.1016/j.eururo.2006.06.034. View

19.

Siegel R, Miller K, Jemal A . Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29. DOI: 10.3322/caac.21254. View

20.

Xylinas E, Ploussard G, Durand X, Fabre A, Salomon L, Allory Y . Low pretreatment total testosterone (< 3 ng/mL) predicts extraprostatic disease in prostatectomy specimens from patients with preoperative localized prostate cancer. BJU Int. 2010; 107(9):1400-3. DOI: 10.1111/j.1464-410X.2010.09816.x. View